BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 30969179)

  • 1. Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype.
    Kim TS; da Silva E; Coit DG; Tang LH
    Am J Surg Pathol; 2019 Jun; 43(6):851-860. PubMed ID: 30969179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
    Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
    Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
    Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
    Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review.
    Bos J; Groen-van Schooten TS; Brugman CP; Jamaludin FS; van Laarhoven HWM; Derks S
    Cancer Treat Rev; 2024 Jun; 127():102737. PubMed ID: 38669788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma: An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors.
    Iwasaki A; Shinozaki-Ushiku A; Kunita A; Yamazawa S; Sato Y; Yamashita H; Fukayama M; Seto Y; Ushiku T
    Am J Surg Pathol; 2021 Sep; 45(9):1213-1220. PubMed ID: 34310369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection.
    Chiaravalli AM; Feltri M; Bertolini V; Bagnoli E; Furlan D; Cerutti R; Novario R; Capella C
    Virchows Arch; 2006 Mar; 448(3):344-53. PubMed ID: 16261379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
    Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
    Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational measurement of tumor immune microenvironment in gastric adenocarcinomas.
    Chang YH; Heo YJ; Cho J; Song SY; Lee J; Kim KM
    Sci Rep; 2018 Sep; 8(1):13887. PubMed ID: 30224753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist.
    Tsuruta S; Ohishi Y; Fujiwara M; Ihara E; Ogawa Y; Oki E; Nakamura M; Oda Y
    Hum Pathol; 2019 Jun; 88():27-38. PubMed ID: 30946937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
    Thompson ED; Zahurak M; Murphy A; Cornish T; Cuka N; Abdelfatah E; Yang S; Duncan M; Ahuja N; Taube JM; Anders RA; Kelly RJ
    Gut; 2017 May; 66(5):794-801. PubMed ID: 26801886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
    Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
    Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?
    Haas M; Büttner M; Rau TT; Fietkau R; Grabenbauer GG; Distel LV
    Virchows Arch; 2011 Apr; 458(4):403-11. PubMed ID: 21359545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8
    Abe H; Saito R; Ichimura T; Iwasaki A; Yamazawa S; Shinozaki-Ushiku A; Morikawa T; Ushiku T; Yamashita H; Seto Y; Fukayama M
    Virchows Arch; 2018 Apr; 472(4):643-651. PubMed ID: 29536167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
    Panda A; Mehnert JM; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Kane M; Sokol L; Stein MN; Poplin E; Rodriguez-Rodriguez L; Silk AW; Aisner J; Chan N; Malhotra J; Frankel M; Kaufman HL; Ali S; Ross JS; White EP; Bhanot G; Ganesan S
    J Natl Cancer Inst; 2018 Mar; 110(3):316-320. PubMed ID: 29155997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.